FirstWord

Earlier this year, CEO Luke Miels singled out felcorekibart as one of the pipeline programmes that could help GSK raise its game.

The deal pairs a Nasdaq listing with Ambros' late-stage pain drug neridronate and an oversubscribed $150M private placement.

The investment is expected to double the facility's size while creating 250 high-wage roles linked to the manufacture drug delivery devices.

Bristol Myers Squibb is the latest pharma giant to tap Chai's AI models, following recent deals with Pfizer, Novartis, Eli Lilly and argenx.

Amplitude Therapeutics will use its trans-amplifying RNA (taRNA) technology to discover infectious disease vaccine candidates.

FirstWord spoke with Mayo Clinic's Vamsi Velcheti about top-line Phase III REZILIENT3 data for Cullinan/Otsuka's zipalertinib, and how it and other anti-EGFR TKIs will impact the treatment of NSCLC with ex20ins.

SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...

Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentationAdditionally, new data...

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today...

According to Fidelity, RBC Capital Markets said Merck & Co.’s momentum remains strong, driven by better-than-expected cancer vaccine data, but its valuation limits further upside.RBC highlighted upcom...